NEW YORK (GenomeWeb News) — Aryx Therapeutics will use GenomeQuest’s sequence search service for use in intellectual property research related to its retrometabolic drug studies, GenomeQuest said today.
GenomeQuest’s software is used by researchers and IP lawyers to evaluate the patentability and competitive landscape for gene sequences.
Jeff Anderson, Aryx Therapeutics’ senior manager of IP, said his company looked to GenomeQuest to simplify the process of understanding the patent landscape that surrounds its IP interests in retrometabolic drug design.
Financial terms of the agreement were not released.